Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval

AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.

Policy Approvals Companies

Sanofi’s Ameet Nathwani Brings Life Sciences R&D Expertise To The Digital Space

Nathwani talks to Scrip about his unique dual role as chief medical officer and chief digital officer, Sanofi’s approach to digital therapeutics, and major hurdles to turning the promise of such technologies into a reality for patients.

Digital Health Exec Chat Artificial Intelligence

No-Deal Brexit 'Very Bad' For Business And Patients

Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.

Brexit Trade Regulation
Advertisement


 Recent Tweets from Scrip


PRECISION MEDICINE RESEARCH: How Advanced Data Analytics Support The Journey From Clinic to Bedside

Precision medicine offers huge promise to patients and health systems. It can also substantially increase the efficiency of drug development by enabling more focused, data-rich clinical trials.

Read more

Embedding Time-Critical Scheduling in Drug Production

Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.

Download Whitepaper
Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement

The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.

Deals Intellectual Property Generic Drugs

Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds

Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.

Financing StartUps and SMEs Business Strategies

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.

South Korea Companies

Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod

Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.

Japan Cancer

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Deals Asia Pacific

Cash Injection Fuels Viela Bio's NMOSD FDA Filing

New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.

BioPharmaceutical Commercial

Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations

Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.

Deals Digital Health

Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal

Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.

M & A Business Strategies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone

The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

Approvals Companies Metabolic Disorders

Korea Steps Up AI Adoption In Drug Discovery, Repositioning And Surveillance

South Korea is stepping up the adoption of artificial intelligence to speed up drug development by selecting discovery, repositioning and smart drug surveillance as three initial focus areas for new AI/big data platforms.

South Korea Artificial Intelligence

USAID Reviewing India Financing Effort With Troubled DHFL

The US Agency for International Development (USAID) is monitoring its Indian healthcare financing initiative with Dewan Housing Finance Corporation amid simmering concerns over the liquidity position of the mortgage lender.

India Financing

How Can Korea Grab Window Of Opportunity In AI Drug Development?

Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.

South Korea Artificial Intelligence

Research & Development Explore this Topic

Set Alert for Research & Development

Tremfya And Taltz Provide PsA Highlights At EULAR

The spotlight was on anti-interleukin drugs at the Madrid meeting last week, especially their role in advancing the treatment of psoriatic arthritis.

Companies Clinical Trials Research & Development

Dosing Woes For VBI Vaccines As Share Price Plummets On Hep B Study Results

Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.

Infectious Diseases Vaccines

Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'

Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases and cancer, including modalities outside of its primary focus on biologics and small molecules.

Research and Development Strategies Cardiovascular

Pipeline Watch: A Phase III Start In Celiac Disease

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
UsernamePublicRestriction

Register

Advertisement